ESMO 2025

Confirmative OS data on CDK4/6 inibitors for pts with…

Rethinking dosing in TNBC

Reassuring data on pregnancy for young EBC patients

Refining the standard treatments for early breast…

A first step into a great story

OS-benefit with abemaciclib

POSITIVE trial - update

Exciting news for young patients who want to get…

T-DXd neoadjuvant improves pCR

First time OS - confirming clinical practice

The first neoadjuvant therapy decreases chemotherapy in…

Optimal timepoint of G-CSF administration after…

Ki67 after preoperative chemotherapy - a new strong…

T-DXd right from the start – in a neoadjuvant situation…

Financial toxicity

Individual consultation remains important

Durvalumab improves OS in TNBC

monarchE OS

Optimizing G-CSF administration helps reducing side…

Great update for young women

T-DXd in high-risk patients in the postneoadjuvant…

New insights into PROTAC SERD vepdegestrant

CDK4/6 inhibitors – confirmed effect

Studio POSITIVE - aggiornamento

Prima valutazione della OS: conferma della pratica…

monarchE OS

Momento óptimo para la administración de G-CSF después…

La primera terapia neoadyuvante reduce la quimioterapia…

Ki67 po przedoperacyjnej chemioterapii - nowy istotny…

ADCs in mBC - the story is not finished

Practice changing data for firstline TNBC

Future perspectives for firstline therapy

Breakthroughs for high-risk patients

TROP2 ADC, the second

Another good option for patients with mTNBC

Reforming destiny

ADC, the first

Survival data from SONIA

Transforming TNBC

Early positioning of third-generation ADCs in treatment

Should this drug be available outside of China?

Gedatolisib in patients with PI3K wild type HR+ mBC

ADCs are coming for first line TNBC

TROP2 number 3

Combination matters

Which ADC in 1L for metastatic TNBC

Changing the paradigm of treatment in 1L of TNBC

Meeting the unmet need in advanced TNBC not eligible…

Nowa szansa dla chorych na zaawansowanego, potrójnie…

Più forti insieme

Cambiando el paradigma del tratamiento en la primera…

Gedatolisib chez les patients atteints d'un cancer du…

Gedatolisib in pazienti con mBC HR+ PI3K wild type

Gli ADC si fanno strada nella prima linea del TNBC

La combinazione conta

Positionnement plus précoce des ADCs de troisième…

Navigating ALK TKI choices in ALK+ NSCLC

Evolving immunotherapy approaches in locally advanced…

New chances for locally advanced NSCLC

A bridge to surgery

FLAURA2: OS outcomes in poor-prognosis EGFRm NSCLC with…

Therapy sequencing after EGFR-TKI progression: insights…

New targeted therapies in HER2-mutated NSCLC

ALEX: Long-term OS benefit with Alectinib in ALK+ NSCLC

HER2 altered - small population, many options

Save and effective - Ivonescimab in HARMONi-6

New treatment options for HER2-mutation positive NSCLC

sac-TMT a new SOC

Local ablative therapy in EGFR-mutated NSCLC

Update for pts with BRAF mutation

The return of antiangiogenic strategy in squamous NSCLC

The added value of radiotherapy in EGFR mutated NSCLC

Is this the end for pembrolizumab?

Ivonescimab in NSCLC - a new SOC?

NorthStar - new navigation principle

Local therapy in addition to osimertinib 1st line in…

EGFR exon 20 - What does the future hold?

Eradication of all disease - is this the true north?

Two frontline HER2-options - is this the future?

New options after EGFR-TKI failure

New chances for locally advanced NSCLC

New kid on the block for EGFRm

Treat your BRAF-patients in 1L

Alectinib remains a potential SOC

Anti-TROP-2 ADCS - new data in EGFRm NSCLC

Sac-TMT now also available for NSCLC

New prospect for squamous tumors

Sac-TMT - a potential new option for EGFRm NSCLC…

ALK - longterm

Two is better than one

New kid on the block for EGFRm

Nuevas perspectivas para los tumores escamosos

Due è meglio di uno

De toegevoegde waarde van radiotherapie bij…

Le retour de la stratégie antiangiogénique dans le…

ADCS anti-TROP-2 - nouvelles données sur le EGFRm NSCLC

È la fine per Pembrolizumab?

Long-term outcomes with tepotinib in METex14 skipping…

Prognostic role of exosomes in stage IIIA(N2) NSCLC…

Tarlatamab combination in 1st line SCLC

Dramatic improvement of PFS in 1L treatment

Will tarlatamab improve 1st line treatment for…

Bending the gravity of SCLC

T-cell engager in 1st line SCLC

Zal tarlatamab de eerstelijnsbehandeling van…

Doblando la gravedad del SCLC

The hippo-pathway in Mesothelioma

Another part of the puzzle

A step in the right direction

The dawn of molecular imaging in renal cell carcinoma

More evidence in second-line treatment for metastatic…

Input for the second line in ccRCC

Relevance of CPI neoadjuvant and adjuvant

LenCabo - early activity, but we need more data

Further intensification of therapy with potential…

Kidney cancer advances from ESMO

Adjuvans in high risk RCC after surgery

MIBC: Practice Changing data towards bladder…

NMIBC: Making the right choice for high risk patients!

MIBC: Is ctDNA monitoring ready for daily practice?

New options for neoadjuvant therapy in MIBC

Negative, but important data to discuss

ADC Enfortumab vedotin + Pembrolizumab in MIBC

Bladder cancer highlights from ESMO 2025

Therapy intensification in patients ineligible for…

Is ICI to BCG suitable for NMIBC?

Setting the bar even higher in MIBC

Better QoL for patients with metastatic bladder cancer

Adding checkpoint inhibitor in high risk NMIBC shows…

De-escalation promotes a better QoL while maintaining…

Neoadjuvant combination of local and systemic therapy…

A newcomer in advanced urothelial cancer

Neoadjuvant HER2-targeted therapy for kidney-sparing…

New benchmark for MIBC and platinum-unsuitable patients

The ADC story continues

Too early for primetime

Perioperative and adjuvant standards for MIBC

A well-tolerated and effective new neoadjuvant concept…

When precision matters, the case of ctDNA in MIBC

Dose modifications, new combinations, new substances in…

Κύρια σημεία για τον καρκίνο της ουροδόχου κύστης από…

Données négatives, mais importantes à discuter

Un recién llegado en el cáncer urotelial avanzado

Cuando la precisión importa: el caso de ctDNA en MIBC

A Game-Changer for Early Relapse?

Triplet regimen with reduced chemotherapy – fewer side…

Practice-changing data for mHSPC

PSMAddition - Is it time for more?

Impressive OS-data from EMBARK

The role of lutetium in mHSPC – is its use clinically…

OS-benefit in BCR

New docetaxel regimen in combination with darolutamide…

Changed chemo-regimen leads to less toxicity in mHSPC

Docetaxel vs. Lutetium in chemosensitive mCRPC

Final OS results for EMBARK

Ändrad kemoterapiregim leder till mindre toxicitet vid…

Exempel på biomarkörstyrd precisionsmedicin vid…

Thymic tumors - heads up